mifepristone
mifepristone: sourced relationships with 1 company · 5 clinical trials tracked · 1 FDA decision.
mifepristone evidence translation
What we can confirm
1 FDA record · 5 tracked trials
What it means
What to watch
Prepared research question
How could mifepristone → CORT affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| CORCEPT THERAPEUTICS INC (CORT) Cushing's syndrome (hypercortisolism) | Approved |
Clinical Trial Registry Records (5)
Prospective Phase III Multi-center Open-label Study of the Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive
Primary endpoint: Overall Pearl Index
A RANDOMIZED, PHASE II STUDY OF ENZALUTAMIDE, ENZALUTAMIDE WITH MIFEPRISTONE, and TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH AR+ METASTATIC TRIPLE-NEGATIVE OR ER-LOW BREAST CANCER
Primary endpoint: progression-free survival (PFS)
RESET-medication: Glucocorticoid Receptor (GR) Blockade As Diseasemodifying Treatment for Depression with Childhood Trauma
Primary endpoint: Depressive symptom severity at post-treatment
Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency
Primary endpoint: Number of Study Participants Recruited
A Phase II Study of Treatment With Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Two or More Previous Chemotherapy Regimens
Primary endpoint: Overall Survival
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with mifepristone?
mifepristone has dated SEC/FDA relationship records for CORCEPT THERAPEUTICS INC.
How many clinical trials involve mifepristone?
BioSniper tracks 5 clinical trials involving mifepristone.
What is mifepristone's latest FDA decision?
The most recent tracked FDA decision for mifepristone is Approval for 1 INDICATIONS AND USAGE KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. LIMITATIONS OF USE: KORLYM should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing's syndrome. KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery ( 1 ). Important Limitations of Use: Do not use for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome., dated February 17, 2012.